An observational study in Diabetes, Obesity & Overweight and Cushing Syndrome, sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain. Recruiting at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain · Observational
Prospective, observational, single-center, study evaluating the prevalence of sarcopenia / sarcopenic obesity in individuals with metabolic and / or endocrine diseases, as well as the potential role of myokines as biomarkers or drivers of sarcopenia / sarcopenic obesity in this population.
.
8,290 studies on the registry are indexed under Diabetes Mellitus; 1,077 are open to participants now.
This study's planned enrollment of 100 is below the median of 246 across 1,936 observational studies indexed under Diabetes Mellitus.
Browse Diabetes Mellitus studies →Cliniques universitaires Saint-Luc- Université Catholique de Louvain is the lead sponsor of 350 studies on the registry; 64 are open to participants now.
Counted across the registry records on this site, refreshed daily.
People with metabolic or endocrine diseases
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants receive GLP-1 RA or GLP-1/GIP dual agonists as part of their standard care for overweight or obesity
Also known as: GLP-1/GIP dual agonists
Prevalence of sarcopenia / sarcopenic obesity
Time frame: From February 2026 to december 2056
Myokines levels in serum or plasma
Myokines levels in serum or plasma as measured by ELISA
Time frame: February 2026 to December 2056
Myokine expression
Myokine expression in muscle as measured by RT-qPCR or RNA-Seq
Time frame: February 2026 to December 2056
Prevalence of MASLD
MASLD as evaluated by Fibroscan, based on controlled attenuation parameter (CAP, in decibels per meter) as a marker of hepatic steatosis
Time frame: March 2026 to December 2056
Prevalence of MASH
Prevalence of MASH as evaluated by Fibroscan, based on Liver stiffness measurement (LSM, in kilopascals) as a surrogate of liver fibrosis
Time frame: March 2026 to December 2056
Plan to share: No
Started Feb 2026 (actual). Primary completion is estimated for Dec 2056, 370 months after the start.
Of 533 non-industry observational studies under Diabetes Mellitus, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 175. This study's planned 370 months is above that.
Counting every sponsor, half of 642 studies reached it within 36 months; a quarter within 14 and three quarters within 122.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cliniques universitaires Saint-Luc- Université Catholique de Louvain →